Innate Pharma annonce une publication dans la revue Science Immunology mettant en avant le NK cell engager ANKET de nouvelle gnration IPH6501
IPHA Stock | USD 1.69 0.11 6.11% |
About 62% of Innate Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding Innate Pharma suggests that many traders are alarmed. The current market sentiment, together with Innate Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Innate Pharma stock news signals to limit their universe of possible portfolio assets.
Innate |
Regulatory News Innate Pharma SA annonce aujourdhui la publication dans Scienc
Read at businesswire.com
Innate Pharma Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Innate Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Innate Pharma Fundamental Analysis
We analyze Innate Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innate Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innate Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Profit Margin
Profit Margin Comparative Analysis
Innate Pharma is currently under evaluation in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Innate Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Innate Pharma stock to make a market-neutral strategy. Peer analysis of Innate Pharma could also be used in its relative valuation, which is a method of valuing Innate Pharma by comparing valuation metrics with similar companies.
Peers
Innate Pharma Related Equities
CSBR | Champions Oncology | 12.09 | ||||
APM | Aptorum Group | 5.33 | ||||
DYAI | Dyadic International | 3.77 | ||||
STTK | Shattuck Labs | 2.31 | ||||
INBX | Inhibrx | 1.00 | ||||
ANEB | Anebulo Pharmaceuticals | 0.64 | ||||
MOLN | Molecular Partners | 0.36 | ||||
ADXN | Addex Therapeutics | 1.38 | ||||
MNOV | MediciNova | 1.74 | ||||
ELYM | Eliem Therapeutics | 1.90 | ||||
IPSC | Century Therapeutics | 4.08 | ||||
HCWB | HCW Biologics | 4.76 |
Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |